^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
The NCCN NSCLC Panel recommends ado-trastuzumab emtansine (category 2A) for patients with ERBB2 (also known as HER2) mutations...
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

The efficacy of Ado-trastuzumab emtansine in HER-2 aberrant non-small cell lung cancer

Excerpt:
Subgroup analyses showed an ORR of 35.00% for HER-2 mutation, 42.86% for HER-2 gene amplification, and 2.78% for HER-2 protein overexpression...T-DM1 is a promising agent targeting HER-2 mutations or amplification in lung cancers, and the therapeutic efficacy may be better for cancers with HER-2 mutation plus amplification.